Healthcare >> CEO Interviews >> April 9, 2001

George Scangos – Exelixis Inc (exel)

GEORGE A. SCANGOS joined Exelixis, Inc., as President and Chief Executive Officer in October 1996 from Bayer Corporation. At Bayer, he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology. As President of Bayer Biotechnology, Dr. Scangos was responsible for 1,100 employees in research and development, business development, process development, manufacturing, engineering, and quality assurance. Prior to Bayer, Dr. Scangos was on the faculty of The Johns Hopkins University where he now holds an appointment as Adjunct Professor of Biology. He serves on the Board of Visitors at the University of California, San Francisco School of Pharmacy, the Board of Overseers at the University of California, Davis Medical School, and the Boards of Directors at Entelos, Inc., Onyx Pharmaceuticals, and Exelixis. Dr. Scangos holds a PhD in Microbiology from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow. Profile
TWST: Could we begin with a brief historical sketch of Exelixis and then

the picture of the company as it is right now?

Dr. Scangos: Exelixis was formally incorporated in 1994. It